Blood Diseases

Aplastic Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Fri, 21 Oct 2022 16:02:05 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Drugs In Development, 2022, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.

Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), co...

$2,000.00

Fanconi Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Fri, 21 Oct 2022 16:02:05 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fanconi Anemia - Drugs In Development, 2022, provides an overview of the Fanconi Anemia (Hematological Disorders) pipeline landscape.

Fanconi anemia (fan-KO-nee uh-NEE-me-uh), or FA, is a rare, inherited blood disorder that leads to bone marrow failure. The disorder also is called Fanconi’s anemia. FA is a type of aplastic anemia. In aplastic anemia, the bone marrow stops making or doesn't make enough of all three types of blood cells. Low levels of the three types of blood cells can harm many of the body's organs, tissues, and systems. Treatment is recommended for significant cytopenias, such as hemoglobin less than 8 g/dL, platelets fewer than 500/μL.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fanconi Anemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Fanconi Anemia (Hematological Disorders), complete with analysis by ...

$2,000.00

Iron Deficiency Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Fri, 08 Apr 2022 11:35:28 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Iron Deficiency Anemia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Iron Deficiency Anemia (Hematological Disorders) pipeline landscape.

Anemia is a condition in which the body does not have enough healthy red blood cells. Iron helps make red blood cells. When body does not have enough iron, it will make fewer red blood cells or red blood cells that are too small. This is called iron deficiency anemia. Symptoms include feeling grumpy, headaches and problems concentrating or thinking. Treatment includes iron supplements and eating iron-rich foods.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Iron Deficiency Anemia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia (Hematological...

$2,000.00

Aplastic Anemia (Hematology) - Drugs in Development, 2021

Tue, 12 Oct 2021 15:07:55 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Drugs In Development, 2021, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), complete wi...

$2,000.00

Fanconi Anemia (Hematology) - Drugs in Development, 2021

Tue, 12 Oct 2021 15:07:55 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fanconi Anemia - Drugs In Development, 2021, provides an overview of the Fanconi Anemia (Hematological Disorders) pipeline landscape.Fanconi anemia (fan-KO-nee uh-NEE-me-uh), or FA, is a rare, inherited blood disorder that leads to bone marrow failure. The disorder also is called Fanconi’s anemia. FA is a type of aplastic anemia. In aplastic anemia, the bone marrow stops making or doesn't make enough of all three types of blood cells. Low levels of the three types of blood cells can harm many of the body's organs, tissues, and systems. Treatment is recommended for significant cytopenias, such as hemoglobin less than 8 g/dL, platelets fewer than 500/μL.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fanconi Anemia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Fanconi Anemia (Hematological Disorders), complete with analysis by stage of ...

$2,000.00

Beta-thalassemia (B-thal) - Pipeline Insight, 2020

Thu, 15 Oct 2020 12:43:30 +0000

This “Beta thalassemia - Pipeline Insight, 2020” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Beta thalassemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Beta thalassemia Understanding Beta thalassemia: Overview Beta thalassemia is a blood disorder that reduces the production of hemoglobin. Hemoglobin is the iron-containing protein in red blood cells that carries oxygen to cells throughout the body. In people with beta thalassemia, low levels of hemoglobin lead to a lack of oxygen in many parts of the body. Affected individuals also have a shortage of red blood cells (anemia), which can cause pale skin, weakness, fatigue, and more serious complications. People with beta thalassemia are at an increased risk of developing abnormal blood clots. Beta tha...

$2,000.00

Warm Autoimmune Hemolytic Anemia (WAIHA) – Pipeline Insight, 2020

Thu, 15 Oct 2020 14:02:56 +0000

DelveInsight’s, “Warm Autoimmune Hemolytic Anemia (WAIHA) – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Warm Autoimmune Hemolytic Anemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Warm Autoimmune Hemolytic Anemia Understanding Warm Autoimmune Hemolytic Anemia (WAIHA): Overview Warm antibody hemolytic anemia is an autoimmune disorder characterized by the premature destruction of healthy red blood cells by autoantibodies. Autoimmune diseases occur when the body's natural defenses against foreign organisms (e.g., lymphocytes, antibodies) destroy healthy tissue for unknown reasons. Normally, red blood cells have a life span of approximately 120 days before they are removed by the spleen. The medical term for low levels of circulating ...

$1,500.00

Chemotherapy Induced Anemia - Pipeline Review, H1 2020

Thu, 07 May 2020 13:39:47 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Anemia - Pipeline Review, H1 2020, provides an overview of the Chemotherapy Induced Anemia (Toxicology) pipeline landscape.

Chemotherapy-induced anemia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. The predisposing factors include age, co-morbidities, time course of therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Anemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), rout...

$2,000.00

Acquired (Autoimmune) Hemolytic Anemia Global Clinical Trials Review, H2, 2018

Fri, 07 Dec 2018 15:32:55 +0000

Summary

GlobalData's clinical trial report, “Acquired (Autoimmune) Hemolytic Anemia Global Clinical Trials Review, H2, 2018" provides an overview of Acquired (Autoimmune) Hemolytic Anemia clinical trials scenario. This report provides top line data relating to the clinical trials on Acquired (Autoimmune) Hemolytic Anemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities an...

$2,500.00

Chemotherapy Induced Anemia - Pipeline Review, H2 2019

Wed, 11 Dec 2019 11:13:09 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Anemia - Pipeline Review, H2 2019, provides an overview of the Chemotherapy Induced Anemia (Toxicology) pipeline landscape.

Chemotherapy-induced anemia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. The predisposing factors include age, co-morbidities, time course of therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Anemia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), rout...

$2,000.00

Iron Deficiency Anemia - Pipeline Review, H1 2019

Tue, 26 Mar 2019 12:29:57 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Iron Deficiency Anemia - Pipeline Review, H1 2019, provides an overview of the Iron Deficiency Anemia (Hematological Disorders) pipeline landscape.

Anemia is a condition in which the body does not have enough healthy red blood cells. Iron helps make red blood cells. When body does not have enough iron, it will make fewer red blood cells or red blood cells that are too small. This is called iron deficiency anemia. Symptoms include feeling grumpy, headaches and problems concentrating or thinking. Treatment includes iron supplements and eating iron-rich foods.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Iron Deficiency Anemia - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and m...

$2,000.00

Competitor Landscape: Renal Anemia

Fri, 21 Dec 2018 11:52:10 +0000

Summary

Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Renal Anemia market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
- Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current develop...

$6,400.00

Global Sickle-Cell Anemia Therapeutics Market Research Report 2018

Fri, 07 Dec 2018 10:39:03 +0000

Sickle-Cell Anemia Therapeutics Report by Material, Application, and Geography – Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). The report firstly introduced the Sickle-Cell Anemia Therapeutics basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world's main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis. The report includes six parts, dealing with: 1.) Basic Information; 2.) Asia Sickle-Cell Anemia Therapeutics Market; 3.) North American Sickle-Cell Anemia Therapeutics Market; 4.) Europe...

$2,850.00

Aplastic Anemia - Pipeline Review, H2 2018

Thu, 29 Nov 2018 15:00:25 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Pipeline Review, H2 2018, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.

Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), comple...

$2,000.00

Fanconi Anemia - Pipeline Review, H2 2018

Thu, 29 Nov 2018 15:00:25 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fanconi Anemia - Pipeline Review, H2 2018, provides an overview of the Fanconi Anemia (Hematological Disorders) pipeline landscape.

Fanconi anemia (fan-KO-nee uh-NEE-me-uh), or FA, is a rare, inherited blood disorder that leads to bone marrow failure. The disorder also is called Fanconi’s anemia. FA is a type of aplastic anemia. In aplastic anemia, the bone marrow stops making or doesn't make enough of all three types of blood cells. Low levels of the three types of blood cells can harm many of the body's organs, tissues, and systems. Treatment is recommended for significant cytopenias, such as hemoglobin less than 8 g/dL, platelets fewer than 500/μL.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fanconi Anemia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Fanconi Anemia (Hematological Disorders), complete with analysis by stag...

$2,000.00

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2017

Thu, 18 Jan 2018 15:45:29 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2017, provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline landscape.

Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness and inability to think clearly.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disord...

$2,000.00

Leukocyte Disorders (White Blood Cell Disorders) Global Clinical Trials Review, H2, 2017

Thu, 18 Jan 2018 13:06:38 +0000

Summary

GlobalData's clinical trial report, “Leukocyte Disorders (White Blood Cell Disorders) Global Clinical Trials Review, H2, 2017" provides an overview of Leukocyte Disorders (White Blood Cell Disorders) clinical trials scenario. This report provides top line data relating to the clinical trials on Leukocyte Disorders (White Blood Cell Disorders). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the d...

$2,500.00

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2016

Fri, 07 Apr 2017 13:51:23 +0000

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Anemia in Chronic Kidney Disease (Renal Anemia) Overview 10
Therapeutics Development 11
Pipeline Products for Anemia in Chronic Kidney Disease (Renal Anemia) - Overview 11
Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics under Development by Companies 12
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Anemia in Chronic Kidney Disease (Renal Anemia) - Products under Development by Companies 19
Anemia in Chronic Kidney Disease (Renal Anemia) - Companies Involved in Therapeutics Development 22
3SBio Inc 22
Acceleron Pharma Inc 23
Aevi Genomic Medicine Inc 24
Akebia Therapeutics Inc 25
Amgen Inc 26
Bayer AG 27
Biocad 28
CCM Duopharma Biotech Bhd 29
Chong Kun Dang Pharmaceutical Corp 30
CJ HealthCare Corp 31
Daiichi Sankyo Company L...

$2,000.00

Chemotherapy Induced Anemia - Pipeline Review, H1 2017

Wed, 05 Apr 2017 15:52:18 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Anemia – Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Anemia (Toxicology) pipeline landscape.

Chemotherapy-induced anemia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. The predisposing factors include age, co-morbidities, time course of therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Anemia – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), r...

$2,000.00

Fanconi Anemia - Pipeline Review, H2 2016

Fri, 09 Dec 2016 10:18:51 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fanconi Anemia - Pipeline Review, H2 2016, provides an overview of the Fanconi Anemia (Hematological Disorders) pipeline landscape.

Fanconi anemia (fan-KO-nee uh-NEE-me-uh), or FA, is a rare, inherited blood disorder that leads to bone marrow failure. The disorder also is called Fanconi’s anemia. FA is a type of aplastic anemia. In aplastic anemia, the bone marrow stops making or doesn't make enough of all three types of blood cells. Low levels of the three types of blood cells can harm many of the body's organs, tissues, and systems. Treatment is recommended for significant cytopenias, such as hemoglobin less than 8 g/dL, platelets fewer than 500/μL.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fanconi Anemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Fanconi Anemia (Hematological Disorders), complete with analysis by stag...

$2,000.00

Epiomic Epidemiology Series: Autoimmune Haemolytic Anemia Forecast in 8 Major Markets 2016-2026

Thu, 06 Oct 2016 11:26:22 +0000

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Autoimmune Haemolytic Anaemia (AIHA) in 8 Major Markets Autoimmune haemolytic anaemia (AIHA) is an immune disorder caused by auto-antibodies against unmodified autologous red blood cells and can range in presentation from a mild illness to a rapidly fatal severe condition. This report provides the current incident population for AIHA across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of AIHA’s have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot. Main symptoms and co-morbidities for AIHA...

$6,400.00

Iron Deficiency Anemia - Pipeline Review, H2 2016

Thu, 15 Sep 2016 21:22:00 +0000

Summary

Global Markets Direct’s, ‘Iron Deficiency Anemia - Pipeline Review, H2 2016’, provides an overview of the Iron Deficiency Anemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conference...

$2,000.00

Sickle Cell Anemia-Market Insights, Epidemiology and Market Forecast-2023

Wed, 24 Aug 2016 13:19:26 +0000

Note*: This report requires 7-10 business days to complete. DelveInsight’s Sickle Cell Anemia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Sickle Cell Anemia for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Sickle Cell Anemia forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Sickle Cell Anemia till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Sickle Cell Anemia market. • Identifying patient populations in the global “Sickle Cell Anemia market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Sickle Cell Anemia therapeutics in each of the mar...

$4,950.00

Thalassemia-Market Insights, Epidemiology and Market Forecast-2023

Wed, 24 Aug 2016 13:19:26 +0000

Note*: This report requires 7-10 business days to complete. DelveInsight’s Thalassemia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Thalassemia for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Thalassemia forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Thalassemia till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Thalassemia market. • Identifying patient populations in the global “Thalassemia market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Thalassemia therapeutics in each of the markets covered. • To understand the future marke...

$4,950.00

Polycythemia-Market Insights, Epidemiology and Market Forecast-2023

Wed, 24 Aug 2016 13:19:26 +0000

Note*: This report requires 7-10 business days to complete. DelveInsight’s Polycythemia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Polycythemia for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Polycythemia forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Polycythemia till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Polycythemia market. • Identifying patient populations in the global “Polycythemia market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Polycythemia therapeutics in each of the markets covered. • To understand the futur...

$4,950.00